Recognizing Patient Readiness for the Next-Line Conversation in Metastatic Castration-Resistant Prostate Cancer

Key Takeaways:

• In the Prostate Cancer 2025 In America survey, 61% of patients actively seek information about new prostate cancer treatments, and 34% plan to discuss a treatment change with their doctor in the next 6 months.
• The same survey's open-ended responses describe an oncologist-driven communication gap at the post-novel-hormonal-therapy (NHT) progression inflection point, with patients characterizing the clinical encounter as hesitant or noncommittal.
• Patient-side readiness for the next-line conversation typically arrives before the oncologist initiates it. Recognizing this inflection earlier – and structuring the conversation proactively – aligns with patient-centered communication recommendations in current advanced prostate cancer guidance.

Clinical assessments of when a patient is "ready" to discuss next-line treatment in metastatic castration-resistant prostate cancer (mCRPC) often arrive a step behind the patient.

The 2025 In America survey, conducted across the ProstateCancer.net community, documents a consistent asymmetry: patients on or approaching progression on a first novel hormonal therapy (NHT) describe themselves as actively seeking treatment information and planning to discuss changes, while the same patients' open-ended responses characterize the oncologist conversation at that inflection point as hesitant or noncommittal. For the HCP audience, this asymmetry is a patient-identification cue worth recognizing.¹

Signals of patient readiness

In the 2025 In America survey, the metastatic cohort includes 206 respondents and provides a quantitative signal on what patients say about treatment information and planning:¹

• 61% of respondents strongly agreed that they actively seek out information about the latest prostate cancer treatments.
• On treatment-change planning over the next six months, 34% strongly agreed they plan to speak with their doctor about changing or adding to their treatment plan.

Both items track elevated patient engagement at a level that maps onto active decision-readiness, not passive treatment continuation. Worry was also non-trivial: 28% reported high worry about their physical health.¹

In the context of the broader symptom burden documented elsewhere in the same dataset, these signals describe a patient population paying close attention to the trajectory of their disease and the implied next steps.¹

The communication-gap pattern

The open-ended responses in the same survey describe what that engagement runs into. One patient observes that his oncologist "seems a bit hesitant to discuss the future phases of my cancer as it progresses" and "is soon to be pressed for his best guess."¹

For a different respondent – watching his prostate-specific antigen (PSA) climb from 0.02 to 0.28 over 11 months on enzalutamide – the gap reads as outright noncommittal: His oncologist "will not commit to next treatment, whether it will be chemo or" an alternative NHT.¹

These patients have done the work that the clinical encounter has not. They have noticed the PSA trajectory, recognized that the current line is losing effect, and arrived at the decision moment ahead of their clinician. The directness another respondent uses – "I wish my provider would tell me my prognosis" – captures the asymmetry plainly.¹

Opening the conversation earlier

The clinical reframe for healthcare providers is to treat rising PSA on a first NHT, early radiographic change, or expressed patient interest in treatment information as a signal that the next-line conversation can be opened – not as a sign that progression has not yet "arrived."

The NCCN Prostate Cancer guideline and the AUA Advanced Prostate Cancer guideline both emphasize multidisciplinary care and structured patient communication across the advanced prostate cancer continuum, and the ASCO endorsement of the Cancer Care Ontario bone-health guideline reinforces the value of shared decision-making in this population.^2-4

Three potential reframings that may help in practice:^2-4

• When PSA is rising on the current NHT, the next-line conversation is usually already on the patient's mind. Opening with "What questions do you have about what comes next?" can surface decision-readiness signals earlier.
• Patient-initiated questions about chemotherapy, radioligand therapy, or alternative classes are often signals of readiness rather than premature concern – and can structure a fuller next-line discussion at the current visit rather than the next one.
• A structured, time-boxed next-line conversation aligns the patient's information-seeking energy with the clinical decision framework.

Recognizing the asymmetry between patient-side readiness and clinical-side timing – and adjusting the clinical encounter to match – is worth the time and effort in mCRPC patients.